Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Abroad (travel likely)RecruitingPHASE3

Conditions

Pancreatic Cancer · Pancreatic Cancer Metastatic · PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · Pancreatic Ductal Adenocarcinoma (PDAC) · Pancreatic Adenocarcinoma Metastatic · Pancreatic Adenocarcinoma · Pancreatic Adenosquamous Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Brian Wolpin) · DanielleA_Lindquist@DFCI.HARVARD.EDU · 857-215-2351
Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States
Contact: Study coordinator (Ann Lovelace) · ann.lovelace@usoncology.com · 702-609-9460
Taylor Cancer Research Center, Maumee, Ohio, United States
Contact: Study coordinator (Stephanie Ambrose) · sambrose@toledoclinic.com · 567-402-4502

View source on ClinicalTrials.gov Contact study team (email)